Plain-English translation of NCT06608355 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing NouvNeu001, a new treatment that involves injecting specialized cells directly into specific areas of the brain using precise surgical techniques. The trial will enroll 6 patients with early-onset Parkinson's disease (diagnosed before age 50) to see whether this treatment is safe and whether it can improve movement problems and other symptoms that come with the disease.
Current Parkinson's treatments help manage symptoms but don't stop or reverse the disease. This trial explores whether transplanting new cells into the brain could offer a more fundamental treatment by potentially replacing or repairing damaged nerve cells that control movement.
You likely qualify if…
You likely don't qualify if…
You would undergo a stereotactic neurosurgery procedure in which the medication is injected into targeted areas on both sides of your brain. After surgery, you would take immunosuppressant medications for 24 to 36 weeks to prevent your body from rejecting the transplanted cells. You would also participate in regular follow-up visits and tests to monitor your safety and whether your movement and other symptoms improve over time.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China